

Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in - Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- The Cancer Letter’s most-read stories of 2025
As MAHA-led policies took hold, oncology navigated through uncertainty and turmoil - Mitochondrial-targeting drug attacks cancer cells from within
- With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025











